Amgen

YTD

ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K.

CEO

Robert A. Bradway

CEORobert A. Bradway

Employees

31,500

Employees31,500

Headquarters

Thousand Oaks, California

HeadquartersThousand Oaks, California

Founded

1980

Founded1980

Employees

31,500

Employees31,500

AMGN Key Statistics

Market cap

189.67B

Market cap189.67B

Price-Earnings ratio

24.13

Price-Earnings ratio24.13

Dividend yield

2.82%

Dividend yield2.82%

Average volume

3.72M

Average volume3.72M

High today

$354.42

High today$354.42

Low today

$343.98

Low today$343.98

Open price

$348.21

Open price$348.21

Volume

2.39M

Volume2.39M

52 Week high

$391.29

52 Week high$391.29

52 Week low

$269.77

52 Week low$269.77

Stock Snapshot

With a market cap of 189.67B, Amgen(AMGN) trades at $349.37. The stock has a price-to-earnings ratio of 24.13 and currently yields dividends of 2.82%.

On 2026-06-25, Amgen(AMGN) stock moved within a range of $343.98 to $354.42. With shares now at $349.37, the stock is trading +1.6% above its intraday low and -1.4% below the session's peak.

Trading volume for Amgen(AMGN) stock has reached 2.39M, versus its average volume of 3.72M.

Over the past 52 weeks, Amgen(AMGN) stock has traded between a high of $391.29 and a low of $269.77.

AMGN News

Bloomberg 49m

Inside the FDA’s Effort to Pull an Amgen Drug Over Alleged Data Manipulation - Bloomberg

...

Simply Wall St 11h

Willful Patent Verdict and Possible Treble Damages Could Be A Game Changer For Amgen

In June 2026, a Delaware jury found that Amgen and its subsidiary Teneobio willfully infringed Harbour BioMed’s Grosveld patent, awarding Harbour US$20,203,704...

Nasdaq 1d

Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Key Points Amgen provides a stable, diversified revenue base of nearly $36.7 billion with significant net income. Iovance Biotherapeutics offers high growth p...

Analyst ratings

51%

of 35 ratings

Buy

37.1%

Hold

51.4%

Sell

11.4%

More AMGN News

Simply Wall St 2d

Amgen Stock Could Be 2.1% Undervalued After Patent Verdict

Harbour BioMed’s jury victory in a high profile patent case against Amgen (AMGN) has put fresh legal risk in focus, as the verdict confirmed willful infringemen...

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.